{"analyses":[{"ciNumSides":"TWO_SIDED","groupDescription":"Comparison between arms for Day 28 of treatment -ESS","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.840","statisticalMethod":"Wilcoxon (Mann-Whitney)","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"Day 1 vs. Day 28 of treatment for the Placebo-First arm-ESS","groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.050","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"Day 1 and Day 28 of treatment for the Armodafinil arm- ESS","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.051","statisticalMethod":"Wilcoxon (Mann-Whitney)","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"Day 28 vs. Day 56 of treatment for the Armodafinil arm","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.635","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.1","value":"12.2"},{"groupId":"OG001","spread":"4.5","value":"11.5"}]}],"title":"Day 1(n=18, 23)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.1","value":"10.1"},{"groupId":"OG001","spread":"4.6","value":"10.0"}]}],"title":"Day 28 (n=19, 23)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.5","value":"11.5"},{"comment":"Day 56 data was only evaluated for the Armodafinil arm","groupId":"OG001","spread":"NA","value":"NA"}]}],"title":"Day 56 (n=15)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"Survey assessing sleep patterns. The test consists of 8 items. The response scale range is 0-24 (range 0-3 per item: 0-No chance to falling asleep; 3-high chance of falling asleep). Interpretation: 0-No chance to falling asleep; 10+ above average chance daytime sleepiness","dispersionType":"Standard Deviation","groups":[{"description":"The patients receive armodafinil for all 56 days of the study.\n\nArmodafinil taken orally at 150 mg daily.","id":"OG000","title":"Armodafinil"},{"description":"These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).\n\nPlacebo taken orally at 150 mg daily. Armodafinil taken orally at 150 mg daily.","id":"OG001","title":"Placebo-First"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Day 1, Day 28 and Day 56","title":"Epworth Sleepiness Scale (ESS) Score","type":"SECONDARY","unitOfMeasure":"units on a scale"}